forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

forREAL: FORXIGA (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) PRESCRIPTION EVENT MONITORING PROGRAM

The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control

Observational Model: Other: A post-marketing evaluation of the safety of Forxiga through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice

Inclusion Criteria:

Patients with Type 2 Diabetes who are:

• Prescribed Forxiga for glycaemic management AND
• Who have the ability to provide informed consent

Exclusion Criteria:

Patients with whom use of Forxiga is contraindicated:

• Patients with Type 1 Diabetes
• Patients with moderate to severe renal impairment [Creatinine clearance (CrCl) <60 mL/min or estimated glomerular filtration rate (eGFR) <60mL/min/1.73m²]

Additional exclusion criteria:

• Age >75 years
• Concomitant use of loop diuretics or pioglitazone
• Patients who are currently on another SGLT2 inhibitor